Sarepta Therapeutics Inc (SRPT) USD0.0001
Sell:$114.41Buy:$114.45
$1.91
(1.65%)
0.25%- This stock can be held in a
Stocks and Shares ISA$1.91
(1.65%)$1.91
(1.65%)Company Information
About this company
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
Key people
Key facts
- EPIC-
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS8036071004
- Market cap$11.22bn
- Employees1,314
- Shares in issue95.52m
- ExchangeNASDAQ
- IndexS&P 400 Mid Cap, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.